Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SmofKabiven vs Hospital Compounded PN in Surgical Patients
NCT03792100Phase 3Completed
- Sponsor
- Fresenius Kabi
- Start
- Jan 2019
- Primary completion
- Jan 2020
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of SmofKabiven Peripheral in Malnutrition (2 arms), sponsored by Fresenius Kabi. Primary endpoint: Change in Serum Prealbumin Level at 6 days. Started Jan 2019; status: completed.
02
Drugs
SmofKabiven Peripheral
03
Conditions
Malnutrition
Beyond the preview
Go deeper on NCT03792100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03792100.